×
Third-quarter 2026 revenue rose 6% year over year to approximately $7.6 million, missing analyst consensus estimates. The company reported a GAAP (generally accepted accounting principles) net loss of $0.09 per share, versus a consensus expectation of a $0.01 profit.
The central $28.50 target is the arithmetic mean of two verified analyst price targets: Northland at $27 and Craig-Hallum at $30, both issued in August 2026. With the stock recently trading near $21.19, reaching $28.50 implies roughly 34% upside—a substantial move for a micro-cap company.
Revenue rose 6.0% year over year to $64.9 million, roughly in line with analyst estimates. Diluted EPS (earnings per share) fell to $0.27 from $0.72 a year earlier, while adjusted diluted EPS of $0.57 declined from $1.19.
Aveanna Healthcare Holdings reported third-quarter 2026 revenue of $695.5 million , up 11.8% year over year and above the consensus estimate of roughly $679.5 million. Adjusted earnings per share (EPS) came in at $0.23 , beating the analyst consensus of $0.21 by $0.02.
The central target of $15 is the arithmetic mean of eight verified, current analyst price targets, and implies roughly 22.5% upside from the latest price near $12.24. Individual targets used span a relatively narrow range of $13 to $16, with most firms clustered at $14 to $16.
AMS shares have fallen roughly 17% over the past 30 days, sliding from about $1.27 to approximately $1.06, with the decline accelerating after a third-quarter earnings miss. A weaker-than-expected third-quarter report was the primary near-term catalyst, as the company posted EPS of -$0.09 versus a consensus estimate of $0.03.
P3 Health Partners shares fell roughly 35% over the last 30 days, sliding from about $4.03 to near $2.63, despite a headline-beating third-quarter earnings report. The sharp decline followed renewed concerns over higher medical costs, a shrinking at-risk membership base, and a reduced earnings-quality picture once one-time items are excluded.
PIII shares declined roughly 34% over the last 30 days, falling from about $4.03 to near $2.64, extending a steep multi-month selloff. The slide accelerated after third-quarter 2026 results reported on November 9, with the stock dropping more than 20% in back-to-back sessions despite a headline earnings beat.
GMRS rose +0.36% during regular market hours, edging from a previous close of $10.99 to an intraday $11.03 — barely a move for this name. No verified news or fundamental catalyst found. The tiny gain is consistent with consolidation after a roughly two-session post-earnings slide that cut the stock more than -10%.
The central target of $19 is the arithmetic mean of eight verified analyst price targets (approximately $18.88, rounded to $19). The latest verified close is about $10.99 , so reaching $19 would require roughly 73% upside — a very large move.
GMR Solutions is the nation's largest emergency medical services (EMS) provider, operating ground and air ambulance operations across roughly 1,400 U.S. counties. Shares moved about +3.7% over the trailing 30 days, holding a relatively narrow range around $11 per share after a choppy post-earnings reaction.
P3 Health Partners reported third quarter 2026 total revenue of $396.3 million , up 15% year over year, beating the consensus estimate of roughly $385 million. The company swung to net income of $30.8 million , compared with a net loss of $69.5 million in the prior-year quarter.
The central $18 stock price target is the arithmetic mean of two current analyst targets: TD Cowen's $13 (Hold) and Lake Street's $23 (Buy). With shares trading near $4.25, reaching $18 would require a gain of roughly 324% — a very large move for a company with a market value of only about $30 million.
The $2.40 central target is the arithmetic mean of four verified analyst price targets, which range from $1.00 to $3.00. With the stock near $0.25, reaching $2.40 would require an upside of roughly 860% — a very large move by any standard.
DocGo reported third quarter 2026 revenue of $73.4 million, up 3.7% year over year but below Wall Street's roughly $78.7 million consensus estimate. Net loss narrowed to $18.1 million from $29.7 million a year earlier, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) improved to a loss of $3.2 million from a loss of $7.2 million.
The central target used here is $19 , the arithmetic mean of eight verified Wall Street price targets, rounded from $18.88. The analyst price target range is wide — roughly $14 to $30 — reflecting genuine disagreement about the company's growth and deleveraging outlook.
The $28 central target comes from public merger discussion — an unsolicited, non-binding third-party cash offer reported by Reuters — rather than from an analyst consensus. Analyst price targets, which averaged roughly $19 to $23 and ranged from about $14 to $24, were largely published before the merger talks intensified and now sit near or below the share price; they are provided as context only, not as the target.
Surgery Partners reported third quarter 2026 revenue of $815.3 million , down about 0.8% from $821.5 million a year earlier and below consensus estimates near $846 million. GAAP net loss attributable to common stockholders was $21.1 million , or $0.16 per share, compared with a loss of $22.7 million in the prior-year quarter.
Surgery Partners, Inc. (SGRY) is a healthcare services company that operates ambulatory surgery centers (ASCs), surgical hospitals, and physician partnerships across more than 200 locations in 30 states. The central $23.50 target used here is the all-cash merger consideration agreed to with HealthSpan Partners, not an average of analyst price targets; the stock is being taken private at $23.50 per share in cash.
Surgery Partners shares jumped from a prior close of $23.20 to $26.19, a +12.89% gain during regular trading hours. The company and HealthSpan Partners announced an amended merger agreement lifting the all-cash buyout to $25.00 per share (up to $26.61 with a ticking fee), after receiving an unsolicited $28-per-share rival bid.